SCYNEXIS (SCYX) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed SCYNEXIS (SCYX) over the past year, losing 18.2% versus a loss of 32.1%. Over five years, SCYX leads with a -90.5% price change compared with -94.7% for TLPH. Talphera is the larger company by market cap ($56.1 million vs $42.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | TLPH |
|---|---|---|
| Share price | $4.22 | $1.08 |
| Market cap | $41.99M | $56.06M |
| 1-day change | -11.72% | +2.86% |
| YTD return | -16.53% | -5.26% |
| 1-year return | -32.11% | -18.18% |
| 5-year return | -90.53% | -94.71% |
| EPS (TTM) | $-0.89 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $1.57 |
| 52-week low | $3.53 | $0.69 |
| Distance from 52-week high | -53.73% | -31.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +760.90% | +189.81% |
| Average volume | 279.10K | 238.38K |
| Shares outstanding | 9.95M | 51.91M |
| Employees | 18 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed SCYX by 13.9 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
SCYX vs TLPH FAQ
Which is bigger, SCYNEXIS or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, SCYX or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -32.11% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and Talphera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.